Global Information
회사소개 | 문의 | 비교리스트

세계의 다발성 골수종 치료제 시장(2017-2021년)

Global Multiple Myeloma Drugs Market 2017-2021

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 12월 상품 코드 320943
페이지 정보 영문 86 Pages
가격
US $ 2,500 ₩ 3,021,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,625,000 PDF by E-mail (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,043,000 PDF by E-mail (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 다발성 골수종 치료제 시장(2017-2021년) Global Multiple Myeloma Drugs Market 2017-2021
발행일 : 2016년 12월 페이지 정보 : 영문 86 Pages

세계의 다발성 골수종 치료제 시장은 2017-2021년간 CAGR로 9.19%의 확대가 예측됩니다.

세계의 다발성 골수종 치료제 시장 시장에 대해 조사분석했으며, 시장 규모와 성장률, 시장 동향, 시장 성장 촉진요인·과제, 시장 기회 검증, 주요 벤더 등에 관한 정보를 정리하여 전해드립니다.

제1장 개요

제2장 조사 범위

  • 시장 개요
  • 주요 제품

제3장 시장 조사 방법

  • 조사 방법
  • 경제지표

제4장 서론

제5장 질병 개요

  • 다발성 골수종의 이해

제6장 파이프라인 제품 분석

제7장 시장 구도

  • 시장 개요
  • Five Forces 분석

제8장 시장 세분화 : 치료 방법별

  • 표적요법
  • 생물요법
  • 화학요법
  • 기타

제9장 지역 세분화

제10장 시장 성장 촉진요인

제11장 촉진요인의 영향

제12장 시장이 해결해야 할 과제

제13장 촉진요인과 과제의 영향

제14장 시장 동향

제15장 벤더 구도

  • 경쟁 시나리오

제16장 주요 벤더 분석

  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals
  • 기타 유력 벤더

제17장 부록

  • 약어 리스트

제18장 Technavio 소개

도표

KSA 17.01.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

About Multiple Myeloma Drugs

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

Technavio's analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • AB Science
  • AbbVie
  • Acceleron Pharma
  • Acetylon Pharmaceuticals
  • Adaptimmune Therapeutics
  • Alexion Pharmaceuticals
  • AmpliMed Corporation
  • Array BioPharma
  • Benovus Bio
  • BioInvent
  • Biokine Therapeutics
  • Biotest
  • bluebird bio
  • Bristol-Meyer Squibb
  • Calithera Biosciences
  • CASI Pharmaceuticals
  • Celldex Therapeutics
  • Cellectar Biosciences
  • Chroma Therapeutics
  • Cleave Biosciences
  • Curis
  • Dicerna Pharmaceuticals
  • Eureka Therapeutics
  • F. Hoffmann-La Roche
  • Geron Corporation
  • GlycoMimetics
  • GlaxoSmithKline
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • JW Pharmaceutical
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Merck
  • Midatech Pharma
  • Mirna Therapeutics
  • Molecular Partners
  • MorphoSys
  • NOXXON Pharma
  • Oncoceutics
  • Oncolytics Biotech
  • OncoPep
  • Oncopeptides
  • Ono Pharmaceutical
  • Otsuka Pharmaceuticals
  • Patrys
  • PharmaMar
  • Polyphor
  • Prothena Therapeutics
  • Sanofi
  • Sevion Therapeutics
  • Specialised Therapeutics
  • Spectrum Pharmaceutical
  • SymBio Pharmaceuticals
  • TaiGen Biotechnology
  • Tragara Pharmaceuticals
  • Vaxil Therapeutics
  • Vivolux

Market driver

  • Growing demand for biologic therapies
  • For a full, detailed list, view our report

Market challenge

  • Growing popularity of complementary and alternative medicines (CAM)
  • For a full, detailed list, view our report

Market trend

  • Emergence of nanomedicine platform
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease

PART 06: Pipeline analysis

PART 07: Market landscape

  • Global multiple myeloma drugs market
  • Five forces analysis

PART 08: Market segmentation by therapy

  • Targeted therapy
  • Biologic therapy
  • Chemotherapy
  • Others

PART 09: Geographical segmentation

  • Multiple myeloma drugs market in Americas
  • Multiple myeloma drugs market in EMEA
  • Multiple myeloma drugs market in APAC

PART 10: Market drivers

  • Growing demand for biologic therapies
  • Paradigm shift toward the adoption of novel proteasome inhibitors
  • Presence of large patient pool

PART 11: Impact of drivers

PART 12: Market challenges

  • Growing popularity of complementary and alternative medicines (CAM)
  • High costs affecting the adoption rates of multiple myeloma drugs
  • Adverse effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of nanomedicine platform
  • Advent of microRNA therapeutics
  • Increasing inorganic growth strategies

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Key vendor analysis

  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments of global multiple myeloma drugs market
  • Exhibit 03: Factors affecting the adoption rates of multiple myeloma drugs market
  • Exhibit 04: Pipeline landscape
  • Exhibit 05: Pipeline analysis
  • Exhibit 06: Global multiple myeloma drugs market snapshot
  • Exhibit 07: Global multiple myeloma drugs market 2016-2021 ($ billions)
  • Exhibit 08: Opportunity analysis of global multiple myeloma drugs market
  • Exhibit 09: Opportunity analysis in developed and emerging markets
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Segmentation of global multiple myeloma drugs market by therapy 2016
  • Exhibit 12: Lifecycle analysis of segments in global multiple myeloma drugs market 2016
  • Exhibit 13: Segmentation of global multiple myeloma drugs market based on geography 2016 and 2021
  • Exhibit 14: Multiple myeloma drugs market revenue by geography 2016-2021 ($ billions)
  • Exhibit 15: Market scenario in Americas
  • Exhibit 16: Multiple myeloma drugs market in Americas 2016-2021 ($ billions)
  • Exhibit 17: Market scenario in EMEA
  • Exhibit 18: Multiple myeloma drugs market in EMEA 2016-2021 ($ billions)
  • Exhibit 19: Market scenario in APAC
  • Exhibit 20: Multiple myeloma drugs market in APAC 2016-2021 ($ billions)
  • Exhibit 21: Key drivers and challenges in APAC
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Alternative therapies for multiple myeloma drugs
  • Exhibit 24: Forcefield analysis of drivers and challenges
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: Key factors driving the adoption of nanomedicine
  • Exhibit 27: Factors driving the adoption of miRNA therapeutics
  • Exhibit 28: Key deals in global multiple myeloma drugs market
  • Exhibit 29: Competitive structure analysis of global multiple myeloma drugs market 2015
  • Exhibit 30: Market share analysis in global multiple myeloma drugs market
  • Exhibit 31: Competitive analysis of global multiple myeloma drugs market
  • Exhibit 32: Market penetration of various multiple myeloma drugs manufacturers worldwide (2016)
  • Exhibit 33: Amgen: Key highlights
  • Exhibit 34: Amgen: Strength assessment
  • Exhibit 35: Amgen: Strategy assessment
  • Exhibit 36: Amgen: Opportunity assessment
  • Exhibit 37: Celgene: Key highlights
  • Exhibit 38: Celgene: Strength assessment
  • Exhibit 39: Celgene: Strategy assessment
  • Exhibit 40: Celgene: Opportunity assessment
  • Exhibit 41: Celgene: YoY revenue and growth rate of REVLIMID 2013-2015 ($ billions)
  • Exhibit 42: Celgene: YoY revenue and growth rate of POMALYST 2013-2015 ($ millions)
  • Exhibit 43: Celgene: YoY revenue and growth rate of THALOMID 2013-2015 ($ millions)
  • Exhibit 44: Johnson & Johnson: Key highlights
  • Exhibit 45: Johnson & Johnson: Strength assessment
  • Exhibit 46: Johnson & Johnson: Strategy assessment
  • Exhibit 47: Johnson & Johnson: Opportunity assessment
  • Exhibit 48: Johnson & Johnson: YoY global revenue comparison of VELCADE 2013-2015 ($ billions)
  • Exhibit 49: Novartis: Key highlights
  • Exhibit 50: Novartis: Strength assessment
  • Exhibit 51: Novartis: Strategy assessment
  • Exhibit 52: Novartis: Opportunity assessment
  • Exhibit 53: Takeda Pharmaceuticals: Key highlights
  • Exhibit 54: Takeda Pharmaceuticals: Strength assessment
  • Exhibit 55: Takeda Pharmaceuticals: Strategy assessment
  • Exhibit 56: Takeda Pharmaceuticals: Opportunity assessment
Back to Top
전화 문의
F A Q